Astrazeneca Share News (AZN)

AstraZenca's Enhertu improves breast cancer survival outcomes

(Alliance News) - AstraZeneca PLC said on Monday phase three trials for Enhertu showed positive outcomes in metastatic breast cancer patients and could "redefine how the disease is classified and treated".

AstraZeneca's Enhertu demonstrates 'statistically significant' survival rates in patients with breast cancer

(Sharecast News) - Drugmaker AstraZeneca said its Enhurtu breast cancer drug had demonstrated a "statistically significant and clinically meaningful improvement" in survival a phase three trial versus chemotherapy.

GSK pauses trial of respiratory virus vaccine in pregnant women

Feb 18 (Reuters) - GSK has paused a late-stage trial of its vaccine candidate against the respiratory syncytial virus (RSV) in pregnant women based on safety recommendations from an independent committee, the British drugmaker said on Friday.

UK dividends calendar - next 7 days

Astra and Sanofi's nirsevimab granted accelerated EU assessment

(Alliance News) - AstraZeneca PLC on Thursday said nirsevimab, which is being developed in collaboration with Sanofi SA, has been accepted for accelerated review by the European Medicines Agency.

LONDON BROKER RATINGS: Goldman ups Glencore price target, cuts Pearson

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and Tuesday:

TOP NEWS: AstraZeneca receives approval by EU for biologic Saphnelo

(Alliance News) - AstraZeneca PLC on Wednesday said the EU approved its biologic Saphnelo for the treatment of moderate to severe systemic lupus erythematosus, an autoimmune condition.

LONDON BRIEFING: UK inflation hits 30-year high in January at 5.5%

(Alliance News) - The UK annual inflation figure raced to just shy of a 30-year high in January, figures from the Office for National Statistics showed Wednesday.

AstraZeneca's Saphnelo receives EU approval

(Sharecast News) - Drugmaker AstraZeneca revealed on Wednesday that Saphnelo had received European Union approval as an add-on therapy for the treatment of adult patients with moderate-to-severe, active autoantibody-positive systemic lupus erythematosus.

European shares rebound as risk assets powered by signs of easing Ukraine-Russia tensions

Feb 15 (Reuters) - European stocks pulled back some of their recent losses on Tuesday following reports that some Russian troops near Ukraine were returning to their bases, while some positive corporate updates also boosted sentiment.

UK stocks rise on easing geopolitical tensions, AstraZeneca trial data

Feb 15 (Reuters) - British stocks rose on Tuesday as global risk sentiment improved after reports that Moscow was withdrawing some troops near Ukraine calmed fears of a potential Russian invasion, while positive data from AstraZeneca and strong earnings from mining company Glencore further lifted sentiment.

LONDON MARKET CLOSE: Stocks rise as Russia pulls back some troops

(Alliance News) - Stocks in London ended higher on Tuesday after Russia adopted a more conciliatory tone in the Ukraine crisis in what could be the first major step towards de-escalation after weeks of tensions.

UK health agency says long COVID less common in the vaccinated

LONDON, Feb 15 (Reuters) - Long COVID is less likely to affect vaccinated people than unvaccinated people, a new review of 15 studies by the UK Health Security Agency released on Tuesday has concluded.

AstraZeneca's Lynparza delays progression risk in prostate cancer

(Sharecast News) - Pharmaceutical company AstraZeneca said on Tuesday that results from a recent study revealed that its Lynparza asset reduced the risk of first-line metastatic castration-resistant prostate cancer progression by 34% when used in combination with abiraterone.

AstraZeneca, Merck report positive Lynparza results in prostate cancer

(Alliance News) - AstraZeneca PLC and Merck & Co Inc on Monday reported positive trial results for Lynparza in combination with abiraterone in patients with prostate cancer.